CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Pregabalin was associated with an increased risk for heart failure relative to another widely used gabapentinoid, based on an ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...

To better detect cardiovascular diseases in people, researchers used high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) to simultaneously quantify metabolites in human plasma ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Certara, Inc., a global leader in biosimulation, announced that the European Medicines Agency (EMA) has formally qualified the Simcyp Simulator for use in regulatory submissions across the EU. Certara ...